Brief: Microport Neuroscientific Says FDA Grants Breakthrough Device Designation To Apollo Dream Rapamycin Stent System
18/03/2026 10:30
March 18 (Reuters) - MicroPort NeuroScientific Corp 2172.HK: FDA GRANTS BREAKTHROUGH DEVICE DESIGNATION TO APOLLO DREAM RAPAMYCIN STENT SYSTEM Further company coverage: 2172.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MicroPort NeuroScientific
See all newsBrief: MicroPort NeuroScientific Corp Says Artemis Dream Enters NMPA Green Path
Brief: Microport Neuroscientific To Continue Share Repurchases Up To Hkd100 Million
Brief: Microport Neuroscientific Says FDA Approves Numentm Helia Coil For Marketing
Brief: Microport Neuroscientific Posts FY Profit Attributable Rmb184.5 Million
Brief: Microport Neuroscientific Says FDA Grants Breakthrough Device Designation To Apollo Dream Rapamycin Stent System